STOCK TITAN

Corbus Pharmaceuticals Holdings (CRBP) Stock News, Oct 2025-Apr 2026

CRBP NASDAQ

Corbus Pharmaceuticals Holdings, Inc. reports clinical-stage drug-development news in oncology and obesity. Updates center on CRB-701, a next-generation Nectin-4 antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical, including data presentations in head and neck squamous cell carcinoma and cervical cancer, FDA interactions and Fast Track designations.

Company news also covers CRB-913, a peripherally restricted oral CB1 inverse agonist for obesity, and CRB-601, an anti-integrin monoclonal antibody targeting TGFβ activation. Recurring items include clinical trial disclosures, medical-meeting presentations, management conference appearances, governance changes and operating or financial results.

Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) said it reached broad alignment with the FDA on registrational study designs for CRB-701 in second-line HNSCC and cervical cancer, enabling potential accelerated approval based on objective response rate (ORR) and potential full approval on overall survival (OS).

Updated monotherapy data will be presented at ASCO 2026; a second-line HNSCC registrational study is expected to start in mid-2026. Chief Medical Officer Dr. Dominic Smethurst will step down June 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
none
-
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will join a moderated panel at the BMO 2026 Metabolic Health Summit in New York on March 24, 2026 at 12:45 pm ET.

Corbus is advancing CRB-913, an oral peripherally restricted CB1 inverse agonist that showed rapid weight loss and favorable GI tolerability in a 14-day Phase 1a SAD/MAD study. The company expects to complete a 12-week Phase 1b dose-ranging study (n=240) in summer 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
none
-
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q4 and full‑year 2025 results and a corporate update on March 9, 2026. Key clinical highlights: CRB-701 showed encouraging unconfirmed ORRs (HNSCC 47.6%, cervical 37.5%, bladder 55.6%) and has FDA Fast Track designations. CRB-913 showed 2.9% placebo‑adjusted weight loss at 14 days with favorable GI and neuropsychiatric profiles. Financially, Corbus completed a $75M public offering in Q4 2025 and held $163.3M cash, funding operations into 2028. Anticipated catalysts: CRB-701 and CRB-913 mid‑2026 data readouts; CRB-701 registrational discussions update in Q1 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.23%
Tags
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will present a corporate overview and hold investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference.

The event is virtual on February 25, 2026 with a presentation at 3:20 PM ET; a webcast link will be provided for investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
none
-
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D. will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.

The presentation is scheduled for January 15, 2026 at 8:15 a.m. PST / 11:15 a.m. EST. The company will participate in a presentation and one-on-one investor meetings, and a webcast will be available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
-
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) reported Phase 1a single- and multiple-ascending dose results for oral CB1 inverse agonist CRB-913 in obesity on Dec 11, 2025. The study (SAD n=64; MAD n=48) showed no serious treatment-emergent adverse events, minimal GI effects, and stable daily neuropsychiatric assessments (CSSRS, PHQ-9, GAD-7). In a dedicated obese MAD cohort (150 mg QD, n=12), all 9 treated participants lost weight vs 0/3 placebo, with a placebo-adjusted mean weight loss of 2.9% at Day 14 (individual range 1.3%–4.3%). PK supported once-daily oral dosing. A 12-week Phase 1b dose-finding study (CANYON-1) has been initiated, with completion expected in summer 2026. The company will host a conference call and webcast today at 8:00 am ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.65%
Tags
none
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) will release results from its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of oral CB1 inverse agonist CRB-913 before market open on Thursday, December 11, 2025.

The company will host a conference call and live webcast at 8:00 am ET the same day to review the Phase 1a safety and tolerability data; a replay will be available on the Corbus website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.65%
Tags
earnings date
-
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q3 2025 results and a corporate update on Nov 12, 2025. The company presented CRB-701 dose-optimization data at ESMO 2025 showing ORRs at 3.6 mg/kg of 47.6% in HNSCC, 37.5% in cervical cancer, and 55.6% in bladder cancer. Corbus plans an FDA meeting in Q1 2026 and expects to start a Phase 2/3 registrational study by mid-2026; CRB-701 has Fast Track designation for HNSCC and metastatic cervical cancer.

The company closed a public offering raising net proceeds of approximately $73.8M (total offering $75M), reporting $104.0M cash on 9/30/25 and stating runway into 2028. CRB-913 SAD/MAD readout and Phase 1b start expected by end of 2025. Q3 net loss was $23.3M versus $13.8M a year earlier.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.39%
Tags
-
Rhea-AI Summary

Corbus Pharmaceuticals (Nasdaq: CRBP) will participate in three investor conferences in November–December 2025 with presentations and one-on-one meetings.

Schedule: Guggenheim Healthcare Innovation Conference in Boston on Nov 12, 2025 at 1:00 PM ET; Jefferies Global Healthcare Conference in London on Nov 18, 2025 at 4:00 PM GMT; Evercore 8th Annual Healthcare Conference in Miami on Dec 2, 2025 at 3:50 PM ET. Each event will offer a webcast (links provided by the company).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
conferences
Rhea-AI Summary

Corbus Pharmaceuticals (Nasdaq: CRBP) priced an underwritten public offering to raise approximately $75 million before underwriting discounts and expenses. The offering consists of 4,744,231 shares of common stock and pre-funded warrants to purchase 1,025,000 shares at $12.9999 each, with an exercise price of $0.0001 per share. Underwriters have a 30-day option for up to 865,384 additional shares. Closing is expected on or about November 3, 2025. Proceeds are intended to fund clinical development, working capital, and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.09%
Tags

FAQ

What is the current stock price of Corbus Pharmaceuticals Holdings (CRBP)?

Corbus Pharmaceuticals Holdings (CRBP) last closed at $2.75.

What is the market cap of Corbus Pharmaceuticals Holdings (CRBP)?

The market cap of Corbus Pharmaceuticals Holdings (CRBP) is approximately $56.6M.